Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Morphine
Drug ID BADD_D01498
Description Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805.[A176035] It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse.[A176050] Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [fentanyl], [methadone], [hydrocodone], [hydromorphone], [meperidine], and [oxycodone]. Morphine was granted FDA approval in 1941.[L12114]
Indications and Usage For the relief and treatment of severe pain.
Marketing Status Prescription; Discontinued
ATC Code N02AA01
DrugBank ID DB00295
KEGG ID D08233
MeSH ID D009020
PubChem ID 5288826
TTD Drug ID D0WE3O
NDC Product Code 42799-217
Synonyms Morphine | Morphia | Morphine Chloride | Chloride, Morphine | Morphine Sulfate | Sulfate, Morphine | SDZ 202-250 | SDZ 202 250 | SDZ 202250 | SDZ202-250 | SDZ202 250 | SDZ202250 | Morphine Sulfate (2:1), Pentahydrate | MS Contin | Contin, MS | Oramorph SR | Duramorph | Morphine Sulfate (2:1), Anhydrous
Chemical Information
Molecular Formula C17H19NO3
CAS Registry Number 57-27-2
SMILES CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Cardiac arrhythmiasMu-type opioid receptorP35372T477688383026; 1528399; 1654493; 8490741; 1279757; 7521466
Cardiac arrhythmiasMu-type opioid receptorP35372T4776825806604
HyperpathiaProtein kinase C alpha typeP17252T1280825806604
HyperpathiaMu-type opioid receptorP35372T477688383026; 1528399; 1654493; 8490741; 1279757; 7521466
HyperpathiaTranscription factor JunP05412T6908525806604
HyperpathiaMu-type opioid receptorP35372T4776825806604
HyperpathiaMitogen-activated protein kinase 8P45983T4009725806604
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Neoplasm malignant16.16.01.001--Not Available
Nervous system disorder17.02.10.0010.003280%Not Available
Nervousness19.06.02.003--Not Available
Neuralgia17.02.07.0050.001640%
Neurotoxicity17.02.10.002; 12.03.01.0110.002109%Not Available
Neutropenia01.02.03.004--Not Available
Nightmare19.02.03.003--Not Available
Non-cardiogenic pulmonary oedema24.03.08.004; 22.01.03.006--Not Available
Nystagmus06.05.02.006; 17.02.02.0060.000703%
Ocular hyperaemia06.04.05.004--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Oedema peripheral02.05.04.007; 14.05.06.011; 08.01.07.007--
Oliguria20.01.03.0040.000703%Not Available
Opisthotonus17.01.03.0050.000703%Not Available
Oral candidiasis11.03.03.004; 07.05.07.0010.000937%Not Available
Oral discomfort07.05.05.001--Not Available
Oropharyngeal swelling23.04.01.013; 22.04.05.005; 10.01.05.014; 07.05.04.0020.000469%Not Available
Orthostatic hypotension24.06.03.004; 17.05.01.020--Not Available
Osteoarthritis15.01.04.001--Not Available
Oxygen saturation decreased13.02.01.0040.006092%Not Available
Pain08.01.08.004--
Pain in extremity15.03.04.010--
Pallor24.03.04.001; 23.03.03.031; 08.01.03.0320.002577%Not Available
Palpitations02.01.02.003--
Pancreatic carcinoma16.13.10.001; 07.21.09.002--Not Available
Pancreatitis07.18.01.001--
Pancreatitis acute07.18.01.0020.004920%Not Available
Panic attack19.06.04.001--Not Available
Paraesthesia17.02.06.005--
Paranoia19.05.01.005--Not Available
The 11th Page    First    Pre   11 12 13 14 15    Next   Last    Total 21 Pages